Equities

Kaken Pharmaceutical Co Ltd

Kaken Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)4,461.00
  • Today's Change23.00 / 0.52%
  • Shares traded209.00k
  • 1 Year change+35.22%
  • Beta0.4276
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in JPY

The one analyst offering a 12 month price target expects KAKEN PHARMACEUTICAL CO., LTD. share price to fall to 3,600.00 in the next year from the last price of 4,461.00.
High-19.3%3,600.00
Med-19.3%3,600.00
Low-19.3%3,600.00

Dividends in JPY

In 2024, Kaken Pharmaceutical Co Ltd reported a dividend of 150.00 JPY, equaling last years dividend. The analyst covering the company expects dividends of 190.00 JPY for the upcoming fiscal year, an increase of 26.67%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in JPY

KAKEN PHARMACEUTICAL CO., LTD. reported annual 2024 earnings of 212.67 per share on May 14, 2024.
Average growth rate-13.24%
More ▼

Revenue history & estimates in JPY

Kaken Pharmaceutical Co., Ltd. had revenues for the full year 2024 of 72.04m. This was 1.29% below the prior year's results.
Average growth rate-4.97%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.